Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration approval, interest in OVs has been boosted greatly. Nevertheless, despite extensive research, oncolytic virotherapy has shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Meijun, Huang, Jianhan, Tong, Aiping, Yang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911943/
https://www.ncbi.nlm.nih.gov/pubmed/31872046
http://dx.doi.org/10.1016/j.omto.2019.10.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911943/
https://www.ncbi.nlm.nih.gov/pubmed/31872046
http://dx.doi.org/10.1016/j.omto.2019.10.007

Ejemplares similares